OPOttavia Prunas

Ottavia Prunas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ottavia Prunas has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel M. Weinberger

    Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, CT

    3 shared publications
  • Daniel M. Weinberger

    Department of Epidemiology of Microbial Diseases, Yale School of Public Health; New Haven, CT, USA

    3 shared publications
  • Joshua L. Warren

    Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, CT

    3 shared publications
  • Daniel M Weinberger

    Department of Epidemiology, Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University , New Haven, Connecticut , USA

    2 shared publications
  • Janepsy Diaz Tito

    Public Health Institute of Chile Departamento Agencia Nacional de Dispositivos Medicos, Innovacion y Desarollo Santiago , Chile

    2 shared publications
  • Joshua Lindsey Warren

    Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, CT, USA

    2 shared publications

Latest Publications

  • Studying the long-term natural history of diseases using a shape-restricted nonparametric temporal realignment method

    by Joshua L. Warren, Ottavia Prunas, Liangbo Linus Shen

    Understanding the natural course of chronic diseases is a fundamental challenge in clinical science, given that disease onset is often unknown and long-term follow-up is impractical. To address this, statistical methods (i.e., disease progression modeling with temporal realignment) have been introduced to infer the long-term natural history of diseases using short-duration follow-up data. While promising for disease management and treatment development, existing approaches require improvements and extensions to the general framework and a deeper investigation into their statistical properties to ensure a more general and statistically reliable solution. To this end, we introduce Bernstein Polynomial Temporal Realignment (BPTR), a shape-restricted nonparametric regression method that relaxes restrictive assumptions made by some existing approaches. BPTR employs a hierarchical framework to capture individual-level variability, allowing simultaneous estimation of: (i) the individual-specific disease progression rate, (ii) the true timing of disease onset for an individual, and (iii) the monotonic function describing disease progression over time. Additionally, covariates are incorporated to better account for variability in progression rates and disease onset times. Through simulations we find that BPTR can accurately estimate key model parameters across increasingly complex data generating settings. We then apply BPTR to a longitudinal dataset of individuals with geographic atrophy secondary to nonexudative age-related macular degeneration, providing new insights into the long-term progression properties of the disease. The method is implemented in the R package BPTR and provides a flexible tool for analyzing the natural course of a chronic disease.


  • Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV

    by O. Prunas, J. Willemsen, J.L. Warren, L. Bont, J.L. Schwartz, J. Atwell, E. Begier, N. Dean, I. Hirsch, R. Karron, et al.


  • Open Access

    Estimated Population-Level Impact of Pneumococcal Conjugate Vaccines Against All-Cause Pneumonia Mortality Among Unvaccinated in 5 Latin American Countries

    by Ottavia Prunas, Kayoko Shioda, Cristiana M Toscano, Magdalena Bastias, Maria Teresa Valenzuela-Bravo, Janepsy Diaz Tito, Joshua L Warren, Daniel M Weinberger, Lucia H de Oliveira

    Background: Pneumococcal conjugate vaccines (PCVs) provide strong direct protection in children, while limited data are available on their indirect effect on mortality among older age groups. This multicountry study aimed to assess the population-level impact of pediatric PCVs on all-cause pneumonia mortality among children ≥5 years of age, and invasive pneumococcal disease (IPD) cases in Chile. Methods: Demographic and mortality data from Argentina, Brazil, Chile, Colombia, and Mexico were collected considering the ≥ 5-year-old population, from 2000 to 2019, with 1 795 789 deaths due to all-cause pneumonia. IPD cases in Chile were also evaluated. Time series models were employed to evaluate changes in all-cause pneumonia deaths during the postvaccination period, with other causes of death used as synthetic controls for unrelated temporal trends. Results: No significant change in death rates due to all-cause pneumonia was detected following PCV introduction among most age groups and countries. The proportion of IPD cases caused by vaccine serotypes decreased from 29% (2012) to 6% (2022) among people aged ≥65 years in Chile. Discussion: While an effect of PCV against pneumonia deaths (a broad clinical definition that may not be specific enough to measure indirect effects) was not detected, evidence of indirect PCV impact was observed among vaccine-type–specific IPD cases.


  • Open Access

    Evaluating the Association between Routine Pneumococcal Vaccination and COVID-19 Severity among Older Adults in the United States

    by Ottavia Prunas, Andrew Tiu, Shweta Bansal, Daniel M. Weinberger

    Background: The relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Streptococcus pneumoniae remains uncertain. This study investigates the association between routine pneumococcal vaccination and the progression to severe COVID-19 outcomes in a cohort of older adults in the United States. Methods: Our cohort study includes adults aged 65 and older from a subset of adults covered by Medicare in the United States with a documented COVID-19 diagnosis. Logistic regression models were employed to assess the association between pneumococcal vaccination (13-valent conjugate vaccine [PCV13] and 23-valent pneumococcal polysaccharide vaccine [PPSV23]) and COVID-19 severity. Results: Among 90,070 Medicare enrollees with a COVID-19 diagnosis, 28,124 individuals exhibited severe respiratory symptoms or were admitted to the intensive care unit (ICU). The odds ratio (OR) for progression from non-severe symptoms to respiratory symptoms with or without ICU admission with prior PCV13 receipt was 0.91 (95% confidence interval [CI], 0.88, 0.93), the OR for progression from severe respiratory symptoms to ICU critical care with prior PCV13 receipt was 0.92 (95% CI, 0.88, 0.97), and the OR for progression from non-severe symptoms to ICU critical care with prior PCV13 receipt was 0.85 (95% CI, 0.81, 0.90). There was no association between PPSV23 received more than five years before the COVID-19 diagnosis and the COVID-19 outcomes. Conclusions: Overall, our findings indicate moderate to no association between PCV vaccination and COVID-19 severity.


  • Incorporating Data from Multiple Endpoints in the Analysis of Clinical Trials: Example from RSV Vaccines

    by Ottavia Prunas, Joukje E. Willemsen, Louis Bont, Virginia E. Pitzer, Joshua L. Warren, Daniel M. Weinberger

    Background: To meet regulatory approval, interventions must demonstrate efficacy against a primary outcome in randomized clinical trials. However, when there are multiple clinically relevant outcomes, selecting a single primary outcome is challenging. Incorporating data from multiple outcomes may increase statistical power in clinical trials. We examined methods for analyzing data on multiple endpoints, inspired by real-world trials of interventions against respiratory syncytial virus (RSV). Method: We developed a novel permutation test representing a weighted average of individual outcome test statistics (wavP) to evaluate intervention efficacy in a multiple endpoint analysis. We compared the power and type I error rate of this approach to the Bonferroni correction (bonfT) and the minP permutation test. We evaluated the different approaches using simulated data from three hypothetical trials varying the intervention efficacy, correlation, and incidence of the outcomes, and data from a real-world RSV clinical trial. Results: When the vaccine efficacy against different outcomes was similar, wavP yielded higher power than bonfT and minP; in some scenarios the improvement in power was substantial. In settings where vaccine efficacy was notably larger against one endpoint compared with the others, all three methods had similar power. We developed an R package, PERmutation basEd ANalysis of mulTiple Endpoints (PERMEATE), to guide the selection of the most appropriate method for analyzing multiple endpoints in clinical trials. Conclusions: Analyzing multiple endpoints using a weighted permutation method can increase power, whereas controlling the type I error rate compared with established methods under conditions mirroring real-world RSV clinical trials.


  • Open Access

    Estimated population-level impact of pneumococcal conjugate vaccines against all-cause pneumonia mortality among unvaccinated age groups in five Latin American countries

    by Ottavia Prunas, Kayoko Shioda, Cristiana M. Toscano, Magdalena Bastias, Maria Teresa Valenzuela-Bravo, Janepsy Diaz Tito, Joshua L. Warren, Daniel M. Weinberger, Lucia H. de Oliveira

    Background Pneumococcal conjugate vaccines (PCVs) provide strong direct protection in children, while limited data are available on their indirect effect on mortality among older age groups. This multi-country study aimed to assess the population-level impact of pediatric PCVs on all-cause pneumonia mortality among ≥5 years of age, and invasive pneumococcal disease (IPD) cases in Chile. Methods Demographic and mortality data from Argentina, Brazil, Chile, Colombia, and Mexico were collected for various age strata considering the ≥ 5-year-old population, from 2000-2020. IPD cases in Chile were also evaluated. Time series models were employed to evaluate changes in all-cause pneumonia deaths during the post-vaccination period, with other causes of death used as synthetic controls for unrelated temporal trends. Results No significant change in death rates due to all-cause pneumonia was detected following PCV introduction among most age groups and countries. The proportion of IPD cases caused by vaccine serotypes decreased from 29% (2012) to 6% (2022) among ≥65 years in Chile. Discussion While an effect of PCV against pneumonia deaths (a broad clinical definition) was not detected, evidence of indirect PCV impact was observed among vaccine-type-specific IPD cases.

  • Open Access

    Incorporating data from multiple endpoints in the analysis of clinical trials: example from RSV vaccines

    by Ottavia Prunas, Joukje E. Willemsen, Louis J Bont, Virginia E. Pitzer, Joshua L. Warren, Daniel M. Weinberger

    Background: To achieve licensure, interventions typically must demonstrate efficacy against a primary outcome in a randomized clinical trial. However, selecting a single primary outcome a priori is challenging. Incorporating data from multiple and related outcomes might help to increase statistical power in clinical trials. Inspired by real-world clinical trials of interventions against respiratory syncytial virus (RSV), we examined methods for analyzing data on multiple endpoints. Method: We simulated data from three different populations in which the efficacy of the intervention and the correlation among outcomes varied. We developed a novel permutation-based approach that represents a weighted average of individual outcome test statistics ( varP ) to evaluate intervention efficacy in a multiple endpoint analysis. We compared the power and type I error rate of this approach to two alternative methods: the Bonferroni correction ( bonfT ) and another permutation-based approach that uses the minimum P-value across all test statistics ( minP ). Results: When the vaccine efficacy against different outcomes was similar, VarP yielded higher power than bonfT and minP; in some scenarios the improvement in power was substantial. In settings where vaccine efficacy was notably larger against one endpoint compared to the others, all three methods had similar power. Conclusions: Analyzing multiple endpoints using a weighted permutation method can increase power while controlling the type I error rate in settings where outcomes share similar characteristics, like RSV outcomes. We developed an R package, PERMEATE , to guide selection of the most appropriate method for analyzing multiple endpoints in clinical trials.


  • Open Access

    Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel

    by Ottavia Prunas, Daniel M Weinberger, Virginia E Pitzer, Sivan Gazit, Tal Patalon

    Background: The short-term effectiveness of a 2-dose regimen of the BioNTech/Pfizer BNT162b2 vaccine for adolescents has been demonstrated. However, little is known about the long-term effectiveness in this age group. It is known, however, that waning of vaccine-induced immunity against infection in adult populations is evident within a few months. Methods: Leveraging the database of Maccabi Healthcare Services (MHS), we conducted a matched case-control design for evaluating the association between time since vaccination and the incidence of infections, where 2 outcomes were evaluated: documented SARS-CoV-2 infection (regardless of symptoms) and symptomatic infection (COVID-19). Cases were defined as individuals aged 12–16 with a positive polymerase chain reaction (PCR) test occurring between 15 June and 8 December 2021, when the Delta variant was dominant in Israel. Controls were adolescents who had not tested positive previously. Results: We estimated a peak vaccine effectiveness between 2 weeks and 3 months following receipt of the second dose, with 85% (95% confidence interval [CI]: 84–86%) and 90% (95% CI: 89–91%) effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19), respectively. However, in line with findings for adults, waning effectiveness was evident. Long-term protection was reduced to 73% (95% CI: 68–77%) against infection and 79% (95% CI: 73–83%) against COVID-19 3–5 months after the second dose and waned to 53% (95% CI: 46–60%) against infection and 66% (95% CI: 59–72%) against COVID-19 after 5 months. Conclusions: Although vaccine-induced protection against both infection and COVID-19 continues over time in adolescents, the protection wanes with time since vaccination, starting 3 months after inoculation and continuing for more than 5 months.


  • Top Cited Papers
    Open Access

    Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel

    by Ottavia Prunas, Joshua L. Warren, Forrest W. Crawford, Sivan Gazit, Tal Patalon, Daniel M. Weinberger, Virginia E. Pitzer

    The effectiveness of vaccines against COVID-19 on the individual level is well established. However, few studies have examined vaccine effectiveness against transmission. We used a chain binomial model to estimate the effectiveness of vaccination with BNT162b2 [Pfizer-BioNTech messenger RNA (mRNA)-based vaccine] against household transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Israel before and after emergence of the B.1.617.2 (Delta) variant. Vaccination reduced susceptibility to infection by 89.4% [95% confidence interval (CI): 88.7 to 90.0%], whereas vaccine effectiveness against infectiousness given infection was 23.0% (95% CI: −11.3 to 46.7%) during days 10 to 90 after the second dose, before 1 June 2021. Total vaccine effectiveness was 91.8% (95% CI: 88.1 to 94.3%). However, vaccine effectiveness is reduced over time as a result of the combined effect of waning of immunity and emergence of the Delta variant.


  • Open Access

    Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents

    by Ottavia Prunas, Daniel M. Weinberger, Virginia E. Pitzer, Sivan Gazit, Tal Patalon

    Background The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 vaccine for adolescents has been demonstrated. However, little is known about the long-term effectiveness in this age group. It is known, though, that waning of vaccine-induced immunity against infection in adult populations is evident within a few months. Methods Leveraging the centralized computerized database of Maccabi Healthcare Services (MHS), we conducted a matched case-control design for evaluating the association between time since vaccination and the incidence of infections, where two outcomes were evaluated separately: a documented SARS-CoV-2 infection (regardless of symptoms) and a symptomatic infection (COVID-19). Cases were defined as individuals aged 12 to 16 with a positive PCR test occurring between June 15 and December 8, 2021, when the Delta variant was dominant in Israel. Controls were adolescents who had not tested positive previously. Results We estimated a peak vaccine effectiveness between 2 weeks and 3 months following receipt of the second dose, with 85% and 90% effectiveness against SARS-CoV-2 infection and COVID-19, respectively. However, in line with previous findings for adults, waning of vaccine effectiveness was evident in adolescents as well. Long-term protection conferred by the vaccine was reduced to 75-78% against infection and symptomatic infection, respectively, 3 to 5 months after the second dose, and waned to 58% against infection and 65% against COVID-19 after 5 months. Conclusions Like adults, vaccine-induced protection against both SARS-CoV-2 infection and COVID-19 wanes with time, starting three months after inoculation and continuing for more than five months.